Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
BMC Pulmonary Medicine · 2025
DOI: 10.1186/s12890-025-03479-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BMC Pulmonary Medicine, 2025. Verfasst von Linfeng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
INTRODUCTION: Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined. METHODS: We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis. RESULTS: We analyzed nine studies involving 3431 patients, including eight perioperative neoadjuvant immunotherapy combinations for non-small cell lung cancer. For patients without programmed death-ligand 1(PD-L1) selection, Toripalimab plus chemotherapy provided the best Pathological complete response (PCR) benefit (OR = 32.89,95% CI:7.88-137.32), best Major Pathological response (MPR) benefit (OR = 10.25, 95% CI: 5.81-18.10) and best Event-free survival (EFS) benefit (HR = 0.40,95% CI: 0.28-0.57). Nivolumab plus chemotherapy provided the best surgical resection rate (OR = 1.71, 95% CI:0.87-3.40) and pembrolizumab plus chemotherapy provided the best R0 surgical resection rate (OR = 2.20, 95% CI:1.28-3.79). In contrast, the combination of ipilimumab, nivolumab and chemotherapy, and the combination of toripalimab and chemotherapy were associated with the lowest incidence of adverse events of grade 3 or above during neoadjuvant therapy. CONCLUSIONS: Our findings suggest that: Toripalimab plus chemotherapy showed better neoadjuvant efficacy and may have an overall survival benefit, but also increased the incidence of serious adverse events during neoadjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. drliur@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Zheng, G., Hu, Y., Maolan, A., Luo, Y., Li, Y., & Liu, R. (2025). Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-025-03479-2
Vancouver
Wang L, Zheng G, Hu Y, Maolan A, Luo Y, Li Y, et al. Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis. BMC Pulmonary Medicine. 2025. doi:10.1186/s12890-025-03479-2
BibTeX
@article{Wang2025,
author = {Wang, Linfeng and Zheng, Guangda and Hu, Yue and Maolan, Ayidana and Luo, Yue and Li, Yue and Liu, Rui},
title = {Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis},
journal = {BMC Pulmonary Medicine},
year = {2025},
doi = {10.1186/s12890-025-03479-2}
}
EUVIMED